Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA.
Dyslipidemia is one of the major causes of atherosclerosis, although in the last few years an increase in cholesterol control rates has been reported. However, results from the European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) surveys indicate that approximately 50% of the patients with ischemic heart disease still do not attain LDL-cholesterol goals despite the use of lipid-lowering therapy (including statins). Rosuvastatin is a new and potent statin that produces greater reductions of LDL-cholesterol when compared with other agents in this class. Furthermore, rosuvastatin provides additional benefits in the lipid profile such as increased HDL-cholesterol, and decreased triglycerides, total cholesterol, apolipoprotein B and apolipoprotein B:A-1 ratio. Cardiovascular disease is a continuum: from risk factors to subclinical organ damage and finally to overt clinical cardiovascular disease. Several trials have investigated the effects of rosuvastatin along this cardiovascular continuum. The results provided by the GALAXY program emphasize the importance of the early treatment with rosuvastatin in the cardiovascular continuum to achieve the greatest benefit. In this paper, the efficacy and safety of rosuvastatin along the cardiovascular continuum is reviewed.